Actively Recruiting
Evaluation of Intravitreal Corticosteroid Implants for Treatment of Diabetic Macular Edema and Inflammatory Biomarker Analysis
Led by Vanderbilt University Medical Center · Updated on 2026-09-28
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying diabetic macular edema DME and diabetic retinopathy to understand if certain inflammation-related molecules in the eye can serve as markers of these conditions. This Phase 4 interventional study aims to measure levels of specific inflammatory cytokines, such as aqueous PGE2, IL-6, IL-8, FLT-3L, FGF-2, and IL-10, before and after treatment. The research is based on initial data suggesting a link between these biomarkers and DME severity. Participants will receive treatment with intravitreal corticosteroid implants, including dexamethasone 0.7 mg and fluocinolone acetonide 0.19 mg implants. The study will monitor changes in the inflammatory markers over a 12-month period following these injections. The goal is to assess how suppressing inflammation with corticosteroids affects these cytokines in the eye. During the study, participants will undergo assessments to measure the levels of inflammatory cytokines in the eye before and after treatment. The researchers will track these markers over 12 months to evaluate treatment effects. Participants may also be monitored for safety and adherence to follow-up visits. The total study duration extends until March 2029, allowing for thorough observation of treatment outcomes.
CONDITIONS
Brief Title
Corticosteroid for Diabetic Macular Edema (DME) Study
Research Team
S
Stephen J Kim, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here